AOD-9604 vs Semaglutide: Fat Loss Peptides Compared

AOD-9604 and semaglutide are frequently discussed together in weight loss and peptide circles, but they represent entirely different pharmacologic classes with vastly different evidence profiles.

AOD-9604 is a HGH fragment peptide (amino acids 176-191 of human growth hormone) that was developed to stimulate lipolysis without the growth-promoting or insulin-antagonistic effects of full-length HGH. It was designed as a fat-specific compound.

Semaglutide is a GLP-1 receptor agonist (glucagon-like peptide-1) developed by Novo Nordisk. It activates GLP-1 receptors throughout the body, triggering appetite suppression, delayed gastric emptying, and improved insulin sensitivity. It has FDA approval for diabetes (Ozempic) and weight loss (Wegovy).

The fundamental difference: AOD-9604 targets direct lipolysis; semaglutide targets appetite and metabolic regulation. Their evidence landscapes are entirely different.

Semaglutide clinical evidence:

• Phase 3 trials: STEP 1-4 trials, each enrolling 1,500-1,900 patients
• Study duration: 68 weeks of treatment; stratified by baseline weight and comorbidities
• Primary endpoints: Percentage weight loss from baseline
• Results: 15-22% weight loss (average) compared to 2-3% with placebo
• Cardiovascular outcomes: LEADER trial showed 26% reduction in major adverse cardiovascular events
• FDA approvals: Ozempic (diabetes, 2017), Wegovy (weight loss, 2021)
• Published papers: 50+ peer-reviewed publications; extensively scrutinized in top journals
• Real-world data: 2+ years of post-marketing surveillance across millions of patients
• Evidence quality: Robust; gold standard

AOD-9604 clinical evidence:

• Phase 2 trials: Multiple small studies (n=20-40) showing lipolysis in vitro and weight reduction in rodent models
• Phase 2b trial: ONE human trial (ADAF-0904) comparing AOD-9604 to placebo in overweight/obese subjects
• Result: FAILED to meet primary endpoint — no statistically significant difference in fat loss vs placebo
• Study was discontinued; no progression to Phase 3
• Published human data: Approximately 3-5 published human studies, all small; most from developer company
• Post-market surveillance: Minimal; mostly anecdotal reports and compounding pharmacy use
• Evidence quality: Poor to moderate; failed clinical trial is a red flag

The critical difference:

Semaglutide has extensive Phase 3 evidence, FDA approval, and 5+ years of real-world safety data. AOD-9604 failed its pivotal Phase 2b human trial and never advanced. The ADAF-0904 trial failure is the most important clinical fact about AOD-9604.

Semaglutide approval:

• FDA-approved: Yes — Ozempic (GLP-1 RA, type 2 diabetes) and Wegovy (GLP-1 RA, chronic weight management)
• Regulatory route: Full FDA approval through Phase 1, 2, 3 trials spanning 15+ years
• Mechanism approved: GLP-1 receptor agonism for appetite suppression and metabolic improvement
• Market status: Marketed globally; extensive medical infrastructure
• Dosing standardization: Pharmaceutical-grade, pen injectors with exact dosing
• Safety monitoring: FDA post-market surveillance, pharmacovigilance systems
• Insurance coverage: Often covered for diabetes; variable for weight loss

AOD-9604 approval:

• FDA-approved: No
• Clinical trial status: Phase 2b trial failed (ADAF-0904); never proceeded to Phase 3
• Mechanism submitted: Direct lipolysis via HGH fragment
• Regulatory pathway: Investigational; development halted after Phase 2b failure
• Market status: Not approved anywhere; available only as research peptide or compounded product
• GRAS status: Designated as Generally Recognized As Safe (GRAS) for food additive use only — NOT as a drug or therapeutic peptide
• Current availability: Online peptide suppliers; compounding pharmacies; quality highly variable
• Safety monitoring: Essentially none; no post-market surveillance

The GRAS designation for food use does not apply to pharmaceutical use — AOD-9604 as a therapeutic peptide has no regulatory approval.

Semaglutide efficacy (evidence-based):

• Average weight loss: 15-22% of body weight over 68 weeks
• Responder rate: 85-90% of patients lose >5% body weight; 70-75% lose >10%
• Effect on visceral fat: Preferential reduction in visceral (intra-abdominal) fat
• Metabolic effects: Improved HbA1c (5-10% reduction in diabetes), improved lipid profiles
• Durability: Weight maintained during continued use; regain if discontinued
• Onset: Effects visible at 4-6 weeks; maximal by 16-20 weeks
• Mechanism proven: GLP-1 receptor activation confirmed in multiple organ systems

AOD-9604 efficacy (limited data):

• Published animal studies: Stimulates lipolysis in adipocytes; no growth hormone effects
• Phase 2b human trial: No statistically significant fat loss vs placebo (ADAF-0904)
• Small retrospective reports: Anecdotal weight loss claims, but no controlled data
• Proposed mechanism: HGH fragment 176-191 stimulates hormone-sensitive lipase; theoretically sound but clinically unproven in humans
• Onset: Unknown; limited human data
• Durability: Unknown; no long-term human studies

The critical fact:

The ONE Phase 2b human trial of AOD-9604 failed to show efficacy. This is not a minor setback — Phase 2b failure means the drug did not demonstrate clinical benefit, so development stopped. There are no completed Phase 3 trials showing efficacy.

Choose Semaglutide if:

• You want proven, FDA-approved efficacy (15-22% weight loss from Phase 3 trials)
• You need real medical oversight (prescriptions through doctors with monitoring)
• You want pharmaceutical-grade medication (exact dosing, consistent quality)
• You value long-term safety data (5+ years post-market, 5+ million patients)
• You accept cost and side effects (nausea, GI symptoms are common but manageable)

Why avoid AOD-9604:

• Failed clinical trial: The Phase 2b trial did not demonstrate efficacy vs placebo
• No human evidence: Zero Phase 3 data; essentially no rigorous human clinical evidence
• Regulatory dead-end: Never FDA-approved for any indication; development halted
• Quality uncertain: Compounded versions vary widely; no standardization
• Risk unknown: No long-term safety data; no post-market surveillance
• Cost: $200-400/month for uncertain benefit

Direct comparison:

Bottom line:

The evidence strongly favors semaglutide. It has robust Phase 3 efficacy, FDA approval, and years of real-world safety data. AOD-9604, despite its theoretical appeal and lower cost, failed its pivotal human trial and has no clinical evidence of efficacy. Choosing AOD-9604 based on cost or theoretical mechanism is not supported by data.

If semaglutide is unaffordable or contraindicated, explore other GLP-1 agonists (tirzepatide, liraglutide) with proven efficacy rather than AOD-9604.